Drug
Inclisiran clinical trials
Also written KJX839, ALN-PCSSC and Leqvio.
Keep track of what changes. Save the inclisiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
51 studies that test it; most in 2024 (11)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 9 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 11 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 37 · Other 14
Novartis Pharmaceuticals (29) · The Medicines Company (6) · Duke University (2) · University of Oxford (1) · Alnylam Pharmaceuticals (1) · Seoul National University Bundang Hospital (1) · First Affiliated Hospital of Xinjiang Medical University (1) · Jose Seijas Amigo (1)
Often tested with
Tested in the same studies.
Alirocumab (2) · Pelacarsen (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Ezetimibe (1) · Bempedoic acid (1) · Evolocumab (1) · MWX203 (1) · QCZ484 (1)
Studies
Open first, then newest update. How each study uses inclisiran is read from its arms, and is right about nine times in ten.
Testing it · 51
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionRecruitingPhase 4Duke UniversityNCT06909565Written as Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Comparing Inclisiran Versus Statin for Primary AldosteronismRecruitingNot applicableThird Military Medical UniversityNCT07884955Written as inclisiran
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed FormulationRecruitingPhase 1Novartis PharmaceuticalsNCT07626281Written as Inclisiran formulation containing PS80
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesRecruitingPhase 3Novartis PharmaceuticalsNCT05682378Written as Inclisiran
- Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesRecruitingPhase 3Novartis PharmaceuticalsNCT07102628Written as Inclisiran
- Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed DyslipidemiaRecruitingPhase 2Shanghai Minwei Biotechnology Co., LtdNCT07803822Written as Inclisiran Sodium Injection
- Early Intensive Lipid-Lowering With Inclisiran for Plaque Stabilization in Acute Coronary SyndromeNot yet recruitingPhase 4Seoul National University Bundang HospitalNCT07799779Written as Inclisiran
- A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaRecruitingPhase 2Novartis PharmaceuticalsNCT07610278Written as Inclisiran
- Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingPhase 3Novartis PharmaceuticalsNCT06597006Written as Inclisiran
- LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL LoweringRecruitingPhase 4University of California, San DiegoNCT06865885Written as Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi ArabiaNot yet recruitingPhase 4Novartis PharmaceuticalsNCT07684469Written as inclisiran
- Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary PreventionRecruitingPhase 4University Medical Centre LjubljanaNCT07581808Written as Inclisiran
- Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingPhase 3Novartis PharmaceuticalsNCT06597019Written as Inclisiran
- LATAM LOWERS LDL-CRecruitingPhase 4Novartis PharmaceuticalsNCT06501443Written as KJX839
- The Prevent Coronary Artery Disease TrialRecruitingPhase 3Icahn School of Medicine at Mount SinaiNCT06494501Written as Inclisiran
- Effects of Inclisiran Combined with Statins on the Morphology of Coronary Vulnerable PlaquesRecruitingPhase 4Nanjing First Hospital, Nanjing Medical UniversityNCT06338293Written as Inclisiran sodium
- Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid UltrasoundNot yet recruitingPhase 4First Affiliated Hospital of Xinjiang Medical UniversityNCT06586684Written as Inclisiran
- PET Imaging of Inflammation and Lipid Lowering StudyRecruitingNot applicableUniversity of CambridgeNCT04073797Written as Inclisiran
- Continuity of Care Between Primary Care Cardiology and Specialty Services for Patients With Chronic Ischemic Heart DiseaseNot yet recruitingPhase 4Jose Seijas AmigoNCT06421363Written as Inclisiran
- Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)Not yet recruitingNot applicableJena University HospitalNCT05587621Written as statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
See all 51 studies that test inclisiran →
Given in every arm · 1 — inclisiran is usual care beside what is tested
As the comparator · 2 — what is tested is compared with inclisiran
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaCompletedPhase 2CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07421232Written as Inclisiran (Leqvio®) 300mg
- Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsCompletedPhase 3LIB Therapeutics LLCNCT05004675Written as Inclisiran
Codes
What other systems call inclisiran · ClinicalTrials.gg INT006414
- MeSH (NLM) C585830ALN-PCSConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UOW2C71PG5INCLISIRANConfirmed FDA, NLM, Wikidata
- RxNorm 2588243One source FDA
- Wikidata Q48969359inclisiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170062InclisiranOne source FDA
- DrugBank DB14901One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585830 | ALN-PCS | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UOW2C71PG5 | INCLISIRAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2588243 | — | One source FDA |
| Wikidata | Q48969359 | inclisiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170062 | Inclisiran | One source FDA |
| DrugBank | DB14901 | — | One source Wikidata |
Also registered as inclisiran sodium (UNII UPC6BTX7PY · RxNorm 2588259).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.